<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561518</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-TTR02-013</org_study_id>
    <nct_id>NCT04561518</nct_id>
  </id_info>
  <brief_title>ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)</brief_title>
  <acronym>ConTTRibute</acronym>
  <official_title>ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to:&#xD;
&#xD;
        -  Describe epidemiological and clinical characteristics, natural history and real-world&#xD;
           clinical management of ATTR amyloidosis patients&#xD;
&#xD;
        -  Characterize the safety and effectiveness of patisiran as part of routine clinical&#xD;
           practice in the real-world clinical setting&#xD;
&#xD;
        -  Describe disease emergence/progression in pre-symptomatic carriers of a known&#xD;
           disease-causing transthyretin (TTR) mutation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">September 2030</completion_date>
  <primary_completion_date type="Anticipated">September 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>From time of enrollment for up to 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Selected Events of Interest in Patients with Hereditary Transthyretin-mediated (hATTR) Amyloidosis (ATTRv Amyloidosis)</measure>
    <time_frame>From 1 year prior to enrollment for up to 10 years</time_frame>
    <description>Selected events of interest are defined as hepatic events, cardiovascular events, renal events, ocular events and infusion-related reactions in patients diagnosed with ATTRv amyloidosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Care Provider (HCP)-Assessed Polyneuropathy (PND) Disability Score</measure>
    <time_frame>Up to 11 years</time_frame>
    <description>PND Scores: Stage 0=No symptoms; Stage I=Sensory disturbances but preserved walking capabilities; Stage II=Impaired walking capacity, but ability to walk without a stick or crutches; Stage IIIA=Walking with help of 1 stick or crutch; Stage IIIB=Walking with the help of 2 sticks or crutches; Stage IV=confined to wheel chair or bedridden.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCP-Assessed Familial Amyloidotic Polyneuropathy (FAP) Score</measure>
    <time_frame>Up to 11 years</time_frame>
    <description>FAP Scores: Stage 0=No symptoms; Stage I=Unimpaired ambulation; mostly mild sensory, motor and autonomic neuropathy in the lower limbs; Stage II=Assistance with ambulation required, mostly moderate impairment progression to the lower limbs, upper limbs, and trunk; Stage III=Wheelchair-bound or bedridden; severe sensory, motor, and autonomic involvement of all limbs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCP-Assessed Neuropathy Impairment Score of the Lower Limb (NIS-LL) Score</measure>
    <time_frame>Up to 11 years</time_frame>
    <description>The NIS-LL assesses muscle weakness, reflexes and sensation, scored separately for the left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) are scored on 0 to 4 scale (0=normal, 4=paralysis). Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) are scored 0=normal, 1=decreased, or 2=absent. Total possible NIS-LL score ranges 0-88 with higher score=greater impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCP-Assessed Cardiomyopathy</measure>
    <time_frame>Up to 11 years</time_frame>
    <description>Cardiomyopathy will be assessed using New York Heart Association (NYHA) Class: I=No symptoms; II=Symptoms with ordinary physical activity; III=Symptoms with less than ordinary physical activity; IV=Symptoms at rest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Score</measure>
    <time_frame>Up to 11 years</time_frame>
    <description>Norfolk-QoL-DN: The Norfolk QOL-DN questionnaire is a standardized 35-item patient-reported outcomes measure that assesses 6 domains: physical function, large-fiber neuropathy, activities of daily living, symptoms, small-fiber neuropathy, and autonomic neuropathy. The total score ranges from -4 points (best possible quality of life) to 136 points (worst possible quality of life).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>Up to 11 years</time_frame>
    <description>The KCCQ is a 23-item self-administered questionnaire developed to independently measure the patient's perception of health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life within a 2-week recall period. The KCCQ quantifies 6 domains (symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability) and 2 summary scores (clinical and overall summary [OS] scores).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rasch-built Overall Disability Scale (R-ODS)</measure>
    <time_frame>Up to 11 years</time_frame>
    <description>The R-ODS is a 24-item self-administered questionnaire for assessment of the disability a patient experiences. It uses a linearly weighted categorical rating scale that specifically captures domains of activity and social participation limitations in patients.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Transthyretin-Mediated Amyloidosis</condition>
  <condition>ATTR Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Patients with ATTR amyloidosis</arm_group_label>
    <description>Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, will be eligible for the study and will follow routine clinical care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-symptomatic Carriers</arm_group_label>
    <description>Pre-symptomatic carriers with a known disease-causing TTR mutation will be eligible for the study and will follow routine clinical care.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, and pre-symptomatic&#xD;
        carriers with a known disease-causing TTR mutation will be eligible for the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of ATTR amyloidosis or documented known disease-causing TTR mutation for the&#xD;
             cohort of pre-symptomatic carriers&#xD;
&#xD;
          -  Germany Only: Patients must be treated per the summary of product characteristics&#xD;
             (SmPC) for any approved treatment for ATTR amyloidosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current enrollment in a clinical trial for any investigational agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alnylam Clinical Trial Information Line</last_name>
    <phone>1-877-ALNYLAM</phone>
    <email>clinicaltrials@alnylam.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alnylam Clinical Trial Information Line</last_name>
    <phone>1-877-256-9526</phone>
    <email>clinicaltrials@alnylam.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Portugal</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RNAi therapeutic</keyword>
  <keyword>Transthyretin</keyword>
  <keyword>TTR</keyword>
  <keyword>Amyloidosis</keyword>
  <keyword>Hereditary Transthyretin-mediated (hATTR) Amyloidosis</keyword>
  <keyword>hATTR amyloidosis</keyword>
  <keyword>Hereditary ATTR amyloidosis</keyword>
  <keyword>Wild-type amyloidosis</keyword>
  <keyword>wtATTR amyloidosis</keyword>
  <keyword>ATTRv amyloidosis</keyword>
  <keyword>ATTRwt amyloidosis</keyword>
  <keyword>Polyneuropathy</keyword>
  <keyword>Familial amyloid polyneuropathies</keyword>
  <keyword>ATTR</keyword>
  <keyword>Transthyretin amyloidosis</keyword>
  <keyword>TTR-mediated amyloidosis</keyword>
  <keyword>Polyneuropathies</keyword>
  <keyword>Amyloid neuropathies</keyword>
  <keyword>Amyloid neuropathies, familial</keyword>
  <keyword>Amyloidosis, familial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

